Pharmaceutical

Image

Asia-Pacific Biologics Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Published Report
  • Jan 2023
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 207
  • No of Figures: 48

Asia-Pacific Biologics Market, By Class (Tumor Necrosis Factor-Α (TNF) Inhibitors, B-Cell Inhibitors, Interleukin Inhibitors, Selective Co-Stimulation Modulators (Abatacept), and Others), Type (Monoclonal Antibodies (MABs), Therapeutic Proteins, Vaccines, Cellular Based Biologics, Gene Based Biologics, and Others), Route of Administration (Injection and Infusion), Application (Oncology, Autoimmune Diseases, Diabetes, Infectious Diseases, Cardiovascular Diseases, Ophthalmic Conditions, Dermatological Diseases, and Others), Source Material (Humans, Avian Cell Culture, Yeast, Bacteria, Insects Cell Culture, Transgenics, and Others), End User (Hospitals, Specialty Clinics, Academics and Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales, and Third Party Distribution) Industry Trends and Forecast to 2030.

Asia-Pacific Biologics Market

Asia-Pacific Biologics Market Analysis and Insights

Biologics are the drugs produced from living organisms or some components of living organisms. These drugs can be derived from different biological sources, including humans, avian cell culture, yeast, bacteria, and insect cell culture among others. These drugs involve therapeutic proteins, monoclonal antibodies, and vaccines. These drugs can be used to treat different types of chronic conditions, including cancers, inflammatory diseases, metabolic diseases, cardiovascular diseases, and infectious diseases.

Asia-Pacific Biologics Market

Asia-Pacific Biologics Market

Asia-Pacific biologics market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyzes that the market is growing with a CAGR of 11.5% in the forecast period of 2023 to 2030 and is expected to reach USD 141,276.35 million by 2030.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Year

2021 (Customizable to 2020-2016)

Quantitative Units

Revenue in USD Million

Segments Covered

By Class (Tumor Necrosis Factor-Α (TNF) Inhibitors, B-Cell Inhibitors, Interleukin Inhibitors, Selective Co-Stimulation Modulators (Abatacept), and Others), Type (Monoclonal Antibodies (MABs), Therapeutic Proteins, Vaccines, Cellular Based Biologics, Gene Based Biologics, and Others), Route of Administration (Injection and Infusion), Application (Oncology, Autoimmune Diseases, Diabetes, Infectious Diseases, Cardiovascular Diseases, Ophthalmic Conditions, Dermatological Diseases, and Others), Source Material (Humans, Avian Cell Culture, Yeast, Bacteria, Insects Cell Culture, Transgenics, and Others), End User (Hospitals, Specialty Clinics, Academics and Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales, and Third Party Distribution).

Countries Covered

China, Japan, India, Australia, South Korea, Singapore, Malaysia, Indonesia, Thailand, Philippines, Vietnam, and rest of Asia-Pacific.

Market Players Covered

AbbVie Inc., AGC Biologics, BeiGene, Bharat Biotech, BioDiem, Biogen, Biocon, Bristol-Myers Squibb Company, Catalent, Inc., Celltrion Healthcare Co., Ltd., CHIME BIOLOGICS, Cipla Inc., F. Hoffmann-La Roche Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., GlaxoSmithKline plc., Innovent, Intas Pharmaceutical Ltd., Ipsen Pharma, Johnson & Johnson Services, Inc., KM Biologics, MERCK & CO., INC., NBHL ltd., Panacea Biotec, Pfizer Inc., Qilu Pharmaceutical Co., Ltd., Serum Institute of India Pvt. Ltd., Shanghai Henlius Biotech, Inc., Teva Pharmaceutical Industries Ltd., WuXi Biologics, and YL Biologics among others.

Market Definition

Biologics are the drugs produced from living organisms or some components of living organisms that have several advantages compared to other drug types, including small molecules. These are very much target-specific which has enhanced the demand among healthcare professionals. Moreover, the side effects caused are mostly related to exaggerated pharmacological effects, leading to mild health effects. Biologic drugs have also been proven to hold high potential for several therapeutic areas and have revolutionized treatments of several serious illnesses. For instance, Rituximab (chimeric monoclonal antibody) has significantly improved non-Hodkings lymphoma.

The major factor that drives the market growth is the rise in the prevalence of chronic diseases such as diabetes and cancer in developing countries. Furthermore, rise in initiatives by governments and surge in research for new biologics drugs are some of the factors that boost the market growth. However, lack of awareness about healthcare in developing countries is a major factor that restrains the market growth. Conversely, growth opportunities exhibited by emerging economies are expected to offer lucrative opportunities for market expansion in the forecast period.

Asia-Pacific Biologics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

DRIVERS

  • Rising prevalence of chronic diseases such as diabetes and cancers

Chronic diseases are one of the biggest healthcare concerns in the world, claiming an estimated 40 million lives every year, 8.5 million of whom reside in Asia. In Asia-Pacific, cardiovascular diseases, diabetes, cancer, and chronic respiratory conditions are among the most common chronic diseases. This is primarily driven by aging populations and poor lifestyle choices such as the lack of physical activity and tobacco & alcohol consumption.

  • Changes in lifestyle

Lifestyle diseases share risk factors similar to prolonged exposure to three modifiable lifestyle behaviors, smoking, unhealthy diet, and physical inactivity, and result in the development of chronic diseases, specifically heart disease, stroke, diabetes, obesity, metabolic syndrome, Chronic Obstructive Pulmonary Disease (COPD), and some types of cancer.

  • Recent advancements in biologics

Delivery by injection is the most convenient method for biologics delivery. It is not always ideal. This is primarily because of the pharmacokinetics of biologics, which means they are rapidly cleared from systemic circulation.

Co-formulation of therapeutics is an emerging strategy that aims to capitalize on advances in therapeutic effects observed through the co-administration of biologics.

RESTRAINTS

  • Complex manufacturing process of biologics

Biologics drugs are highly complex molecules produced by living cells through a multistep manufacturing process. The key characteristics of these molecules, known as Critical Quality Attributes (CQAs), can vary based on post-translational modifications that occur in the cellular environment or during the manufacturing process. The complexity of the manufacturing process leads to several defaults. Thus, the complex manufacturing process of biologics is acting as a major restraining factor for market growth.

  • Adverse side-effects of biologics

Like standard pharmaceuticals, biological treatments can cause adverse drug reactions. They can cause allergic reactions similar to the ways these drugs can. But they can also cause problems due to the way biologics interact with the immune system. They can also sometimes cause specific issues with various organ systems in the body.

Some of the side effects associated with biologics are:

  • Injection site reactions
  • Infusion reactions

Usually, these reactions are mild. However, sometimes they may be more severe such as hypersensitivity reactions, and require medical intervention.

Thus, adverse side effects of biologics treatment act as a restraint for market growth.

Asia-Pacific Biologics Market

OPPORTUNITIES

  • Rising healthcare expenditure

Across the globe, R&D activities are escalating owing to public health expenditure with economic performance. At the same time, the healthcare industry ranks second among all industries regarding R&D. Rising healthcare expenditure can result in better provision of R&D opportunities. That results in the anticipated upsurging demand for various cancer diagnostics.

  • Strategic initiatives by market players

An increase in the burden of various types of diseases such as cancers, diabetes, and cardiovascular diseases across Asia-Pacific, coupled with the rise in the geriatric population, has created more demand for biologics. The main aim is to improve health management in biologics for quality care with convenient application. Hence, major market players are focusing on fulfilling the demand for biologics and spending a noticeable amount on better products.

Thus, these strategic product launches, acquisitions, and mergers by major companies in the biologics market have opened up opportunities for companies in Asia. This strategy is allowing the companies to strengthen their footprints in the market.

  • Surge in healthcare expenditure

Healthcare expenditure has increased across Asia-Pacific region, as the disposable income of people across Asia is increasing. Moreover, to accomplish the population requirements, government bodies and healthcare organizations are taking initiatives by accelerating healthcare expenditure. The rise in healthcare expenditure simultaneously helps healthcare organizations to improve their treatment facilities for the usage of biologics.

  • Growing number of biopharmaceutical contract manufacturing companies in Asia

The biopharmaceutical contract manufacturing market is growing essentially due to the increasing demand for biologics and increasing outsourcing by pharmaceutical companies in Asia-Pacific. Increasing competition in the industry is likely to damage the market growth in the coming years. Additionally, robust advancements in R&D activities, emerging markets, and consolidation in the pharmaceutical CMO industry are likely to increase the growth of biopharmaceutical contract manufacturing companies during the forecast period.

The growing number of biopharmaceutical contract manufacturing companies leads to the development of new products via rigorous research to treat various diseases. Thus, this acts as an opportunity for market growth.

CHALLENGE

  • Stringent regulatory policies

Regulation of drugs plays a significant role in healthcare. Achieving the requisite approval for the legal selling of medical devices or medications in such jurisdictions can entail substantial financial expenditure, which could take months or years to complete. If these constraints are not understood or taken into account, delays can seriously jeopardize the likelihood of success in a highly competitive market. The biologics such as vaccines, blood and blood components, allergenic, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins among others are of significant importance for treating various diseases. But their approval and marketing in multiple regions across Asia require a meeting of stringent regulatory standards and acceptance by various regulatory bodies.

Thus, the above-mentioned stringent regulations and policies for approving the complicated nature of biologics act as a challenge to market growth.

Post-COVID-19 Impact on Asia-Pacific Biologics Market

The COVID-19 pandemic had somewhat negative impact on the biologics market. Due to the pandemic, new norms and regulations were imposed, such as social distancing and lockdown to prevent the spread of virus. As a result, people all over the world were forced to stay at home. This stay-at-home led to a decrease in the consumption of biologics, which further led to a decrease in the demand for biologics.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the quality of biologics existing in the market.

Recent Developments

Many product launches and agreements are also initiated by companies worldwide which are accelerating the market growth.

  • In November 2021, Biocon launched Interchangeable SEMGLEE (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection in collaboration with Viatris Inc. The new product launch helped patients control high blood sugar in adults and pediatric patients suffering from diabetes 1 and diabetes 2.
  • In December 2019, Bharat Biotech launched ROTAVAC 5D-lowest dose volume rotavirus vaccine across the world. The product launch was developed in partnership with the Department of Biotechnology, Government of India.

Asia-Pacific Biologics Market Scope

Asia-Pacific biologics market is segmented into seven notable segments based on class, type, route of administration, application, source material, end user, and distribution channel.

By Class

  • Tumor Necrosis Factor-Α (TNF) Inhibitors
  • B-Cell Inhibitors
  • Interleukin Inhibitors
  • Selective Co-Stimulation Modulators (Abatacept)
  • Others

Based on class, the market is segmented into tumor necrosis factor-α (TNF) inhibitors, b-cell inhibitors, interleukin inhibitors, selective co-stimulation modulators (abatacept), and others.

By Type

  • Monoclonal Antibodies (mABs)
  • Therapeutic Proteins
  • Vaccines
  • Cellular Based Biologics
  • Gene Based Biologics
  • Other

Based on type, the market is segmented into monoclonal antibodies (mABs), therapeutic proteins, vaccines, cellular based biologics, gene based biologics, and other.

By Route of Administration

  • Injection
  • Infusion

Based on route of administration, the market is segmented into injection, and infusion.

By Application

  • Oncology
  • Autoimmune Diseases
  • Diabetes
  • Infectious Diseases
  • Cardiovascular Diseases
  • Ophthalmic Diseases
  • Dermatological Diseases
  • Others

Based on application, the market is segmented into oncology, autoimmune diseases, diabetes, infectious diseases, cardiovascular diseases, ophthalmic conditions, dermatological diseases, and others.

By Source Material

  • Humans
  • Avian Cell Culture
  • Yeast
  • Bacteria
  • Insects Cell Culture
  • Transgenics
  • Others

Based on source material, the market is segmented into humans, avian cell culture, yeast, bacteria, insect cell culture, transgenics, and others.

By End User

  • Hospital
  • Specialty Clinics
  • Academics and Research Institutes
  • Others

Based on end user, the market is segmented into hospitals, specialty clinics, academics and research institutes, and others.

Distribution Channel

  • Direct Tender
  • Retail Sales
  • Third Party Distribution

Based on distribution channel, the market is segmented into direct tender, retail sales, and third party distribution.

Asia-Pacific Biologics Market

Asia-Pacific Biologics Market Regional Analysis/Insights

The Asia-Pacific biologics market is analyzed and market size information is provided based on country, class, type, route of administration, application, source material, end user, and distribution channel.

In 2022, Asia-Pacific was growing due to the rising prevalence of chronic diseases such as diabetes and cancer. China is expected to dominate the market due to recent advancements in biologics.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Asia-Pacific Biologics Market Share Analysis

Asia-Pacific biologics market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, and technology lifeline curve. The above data points provided are only related to the company’s focus related to the market.

Some of the major players operating in this market are AbbVie Inc., AGC Biologics, BeiGene, Bharat Biotech, BioDiem, Biogen, Biocon, Bristol-Myers Squibb Company, Catalent, Inc., Celltrion Healthcare Co., Ltd., CHIME BIOLOGICS, Cipla Inc., F. Hoffmann-La Roche Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., GlaxoSmithKline plc., Innovent, Intas Pharmaceutical Ltd., Ipsen Pharma, Johnson & Johnson Services, Inc., KM Biologics, MERCK & CO., INC., NBHL ltd., Panacea Biotec, Pfizer Inc., Qilu Pharmaceutical Co., Ltd., Serum Institute of India Pvt. Ltd., Shanghai Henlius Biotech, Inc., Teva Pharmaceutical Industries Ltd., WuXi Biologics, and YL Biologics among others.


SKU-

TABLE 1 REGULATIONS IMPOSED BY SEVERAL REGULATORY AGENCIES IN DIFFERENT COUNTRIES

TABLE 2 ASIA-PACIFIC BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 3 ASIA-PACIFIC TUMOR NECROSIS FACTOR-Α (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 4 ASIA-PACIFIC B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 5 ASIA-PACIFIC INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 6 ASIA-PACIFIC BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 7 ASIA-PACIFIC MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 8 ASIA-PACIFIC THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 9 ASIA-PACIFIC VACCINES IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 10 ASIA-PACIFIC BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 11 ASIA-PACIFIC ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 12 ASIA-PACIFIC OTHERS IN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 13 ASIA-PACIFIC AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 14 ASIA-PACIFIC OTHERS IN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 15 ASIA-PACIFIC BIOLOGICS MARKET, BY SOURCE MATERIAL, 2021-2030 (USD MILLION)

TABLE 16 ASIA-PACIFIC BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 17 ASIA-PACIFIC BIOLOGICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 18 ASIA-PACIFIC BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 19 ASIA-PACIFIC BIOLOGICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 20 CHINA BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 21 CHINA TUMOR NECROSIS FACTOR-Α (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 22 CHINA B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 23 CHINA INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 24 CHINA BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 25 CHINA MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 26 CHINA THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 27 CHINA VACCINES IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 28 CHINA BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 29 CHINA BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 30 CHINA ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 31 CHINA OTHERS IN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 32 CHINA AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 33 CHINA OTHERS IN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 34 CHINA BIOLOGICS MARKET, BY SOURCE MATERIAL, 2021-2030 (USD MILLION)

TABLE 35 CHINA BIOLOGICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 36 CHINA BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 37 JAPAN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 38 JAPAN TUMOR NECROSIS FACTOR-Α (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 39 JAPAN B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 40 JAPAN INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 41 JAPAN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 42 JAPAN MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 43 JAPAN THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 44 JAPAN VACCINES IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 45 JAPAN BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 46 JAPAN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 47 JAPAN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 48 JAPAN OTHERS IN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 49 JAPAN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 50 JAPAN OTHERS IN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 51 JAPAN BIOLOGICS MARKET, BY SOURCE MATERIAL, 2021-2030 (USD MILLION)

TABLE 52 JAPAN BIOLOGICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 53 JAPAN BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 54 INDIA BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 55 INDIA TUMOR NECROSIS FACTOR-Α (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 56 INDIA B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 57 INDIA INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 58 INDIA BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 59 INDIA MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 60 INDIA THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 61 INDIA VACCINES IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 62 INDIA BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 63 INDIA BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 64 INDIA ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 65 INDIA OTHERS IN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 66 INDIA AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 67 INDIA OTHERS IN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 68 INDIA BIOLOGICS MARKET, BY SOURCE MATERIAL, 2021-2030 (USD MILLION)

TABLE 69 INDIA BIOLOGICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 70 INDIA BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 71 AUSTRALIA BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 72 AUSTRALIA TUMOR NECROSIS FACTOR-Α (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 73 AUSTRALIA B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 74 AUSTRALIA INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 75 AUSTRALIA BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 76 AUSTRALIA MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 77 AUSTRALIA THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 78 AUSTRALIA VACCINES IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 79 AUSTRALIA BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 80 AUSTRALIA BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 81 AUSTRALIA ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 82 AUSTRALIA OTHERS IN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 83 AUSTRALIA AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 84 AUSTRALIA OTHERS IN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 85 AUSTRALIA BIOLOGICS MARKET, BY SOURCE MATERIAL, 2021-2030 (USD MILLION)

TABLE 86 AUSTRALIA BIOLOGICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 87 AUSTRALIA BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 88 SOUTH KOREA BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 89 SOUTH KOREA TUMOR NECROSIS FACTOR-Α (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 90 SOUTH KOREA B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 91 SOUTH KOREA INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 92 SOUTH KOREA BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 93 SOUTH KOREA MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 94 SOUTH KOREA THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 95 SOUTH KOREA VACCINES IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 96 SOUTH KOREA BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 97 SOUTH KOREA BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 98 SOUTH KOREA ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 99 SOUTH KOREA OTHERS IN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 100 SOUTH KOREA AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 101 SOUTH KOREA OTHERS IN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 102 SOUTH KOREA BIOLOGICS MARKET, BY SOURCE MATERIAL, 2021-2030 (USD MILLION)

TABLE 103 SOUTH KOREA BIOLOGICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 104 SOUTH KOREA BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 105 SINGAPORE BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 106 SINGAPORE TUMOR NECROSIS FACTOR-Α (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 107 SINGAPORE B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 108 SINGAPORE INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 109 SINGAPORE BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 110 SINGAPORE MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 111 SINGAPORE THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 112 SINGAPORE VACCINES IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 113 SINGAPORE BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 114 SINGAPORE BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 115 SINGAPORE ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 116 SINGAPORE OTHERS IN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 117 SINGAPORE AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 118 SINGAPORE OTHERS IN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 119 SINGAPORE BIOLOGICS MARKET, BY SOURCE MATERIAL, 2021-2030 (USD MILLION)

TABLE 120 SINGAPORE BIOLOGICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 121 SINGAPORE BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 122 MALAYSIA BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 123 MALAYSIA TUMOR NECROSIS FACTOR-Α (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 124 MALAYSIA B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 125 MALAYSIA INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 126 MALAYSIA BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 127 MALAYSIA MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 128 MALAYSIA THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 129 MALAYSIA VACCINES IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 130 MALAYSIA BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 131 MALAYSIA BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 132 MALAYSIA ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 133 MALAYSIA OTHERS IN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 134 MALAYSIA AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 135 MALAYSIA OTHERS IN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 136 MALAYSIA BIOLOGICS MARKET, BY SOURCE MATERIAL, 2021-2030 (USD MILLION)

TABLE 137 MALAYSIA BIOLOGICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 138 MALAYSIA BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 139 INDONESIA BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 140 INDONESIA TUMOR NECROSIS FACTOR-Α (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 141 INDONESIA B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 142 INDONESIA INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 143 INDONESIA BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 144 INDONESIA MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 145 INDONESIA THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 146 INDONESIA VACCINES IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 147 INDONESIA BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 148 INDONESIA BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 149 INDONESIA ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 150 INDONESIA OTHERS IN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 151 INDONESIA AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 152 INDONESIA OTHERS IN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 153 INDONESIA BIOLOGICS MARKET, BY SOURCE MATERIAL, 2021-2030 (USD MILLION)

TABLE 154 INDONESIA BIOLOGICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 155 INDONESIA BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 156 THAILAND BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 157 THAILAND TUMOR NECROSIS FACTOR-Α (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 158 THAILAND B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 159 THAILAND INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 160 THAILAND BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 161 THAILAND MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 162 THAILAND THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 163 THAILAND VACCINES IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 164 THAILAND BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 165 THAILAND BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 166 THAILAND ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 167 THAILAND OTHERS IN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 168 THAILAND AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 169 THAILAND OTHERS IN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 170 THAILAND BIOLOGICS MARKET, BY SOURCE MATERIAL, 2021-2030 (USD MILLION)

TABLE 171 THAILAND BIOLOGICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 172 THAILAND BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 173 PHILIPPINES BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 174 PHILIPPINES TUMOR NECROSIS FACTOR-Α (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 175 PHILIPPINES B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 176 PHILIPPINES INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 177 PHILIPPINES BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 178 PHILIPPINES MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 179 PHILIPPINES THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 180 PHILIPPINES VACCINES IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 181 PHILIPPINES BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 182 PHILIPPINES BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 183 PHILIPPINES ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 184 PHILIPPINES OTHERS IN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 185 PHILIPPINES AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 186 PHILIPPINES OTHERS IN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 187 PHILIPPINES BIOLOGICS MARKET, BY SOURCE MATERIAL, 2021-2030 (USD MILLION)

TABLE 188 PHILIPPINES BIOLOGICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 189 PHILIPPINES BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 190 VIETNAM BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 191 VIETNAM TUMOR NECROSIS FACTOR-Α (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 192 VIETNAM B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 193 VIETNAM INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

TABLE 194 VIETNAM BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 195 VIETNAM MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 196 VIETNAM THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 197 VIETNAM VACCINES IN BIOLOGICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 198 VIETNAM BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 199 VIETNAM BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 200 VIETNAM ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 201 VIETNAM OTHERS IN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 202 VIETNAM AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 203 VIETNAM OTHERS IN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 204 VIETNAM BIOLOGICS MARKET, BY SOURCE MATERIAL, 2021-2030 (USD MILLION)

TABLE 205 VIETNAM BIOLOGICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 206 VIETNAM BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 207 REST OF ASIA-PACIFIC BIOLOGICS MARKET, BY CLASS, 2021-2030 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The Asia-Pacific Biologics Market will be worth USD 141,276.35 million in the forecast period by 2030.
The Asia-Pacific Biologics Market growth rate is 11.5% in the forecast period by 2030.
Changes in lifestyle, Recent advancements in biologics, and the Rising prevalence of chronic diseases such as diabetes and cancers are the growth drivers of the Asia-Pacific Biologics Market.
The class, type, route of administration, application, source material, end user, and distribution channel are the factors on which the Asia-Pacific Biologics Market research is based.
Major companies in the Asia-Pacific Biologics Market are AbbVie Inc., AGC Biologics, BeiGene, Bharat Biotech, BioDiem, Biogen, Biocon, Bristol-Myers Squibb Company, Catalent, Inc., Celltrion Healthcare Co., Ltd., CHIME BIOLOGICS, Cipla Inc., F. Hoffmann-La Roche Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., GlaxoSmithKline plc., Innovent, Intas Pharmaceutical Ltd., Ipsen Pharma, Johnson & Johnson Services, Inc., KM Biologics, MERCK & CO., INC., NBHL ltd., Panacea Biotec, Pfizer Inc., Qilu Pharmaceutical Co., Ltd., Serum Institute of India Pvt. Ltd., Shanghai Henlius Biotech, Inc.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials